Microenvironment in lymphoma pathogenesis and therapy
Featured projects
-
Red transpirenaica de terapias avanzadas en linfoma no Hodgkin (THERAVLINFO)
Principal investigator: Patricia Pérez Galán.Code: EFA 123/1.Duration: 01/01/2024 - 31/12/2025Vascularized lymphoma on-chip: a multifaceted tool for translational research (MyLymphoTool)
Code: HR22-00395.Duration: 01/12/2022 - 30/11/2025Dual CD19-CAR-T approaches to counteract antigen escape and tumor microenvironment immune suppression in FL
Code: INT_Milken_FLF_22.Duration: 01/12/2022 - 30/11/2024Vascular and extracellular matrix remodeling in follicular lymphoma: implications in the transformation to an aggressive lymphoma and immunotherapy efficacy (VASCEM_LYMPHO)
Code: PID2021-124894OB-I00.Duration: 01/09/2022 - 31/08/2025Patient Derived Organoids 2.0: Annotated immunocompetent organoid platforms in solid and hematological tumors as living labs for the optimization and design of current and novel immunotherapies and cellular therapies. CIBERONC (Strategic Action-Towards Ca
Principal investigator: Patricia Pérez Galán.Duration: 01/07/2021 - 01/07/2023Characterization of duvelisib activity in follicular lymphoma and macrophages crosstalk
Principal investigator: Patricia Pérez Galán.Funder: Janssen Pharmaceuticals .Duration: 01/01/2020 - 31/12/2020Multi-cellular interactions in the progression of chronic inflammatory diseases and lymphoproliferative disorders: 3D models to investigate targeted immune therapies -3DIMMUNETARGET
Principal investigator: Maria Cinta Cid Xutgla, Patricia Pérez Galán.Funder: Ministerio de Economia y Competitividad (MINECO) .Code: SAF 2017- 88275-R.Duration: 01/01/2018 - 31/12/2020Cross-border network of personalized immunotherapies in Non-Hodgkin Lymphoma -IMLINFO (POCTEFA-INTERREG).
Principal investigator: Patricia Pérez Galán.Funder: INTERREG V-POCTEFA .Code: EFA281/16.Duration: 01/01/2018 - 31/12/2021Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention
Principal investigator: Patricia Pérez Galán.Funder: Ministerio de Economía y Competitividad .Code: SAF 2014/57708R.Duration: 01/01/2015 - 01/01/2018Characterization of the mechanisms of microenvironment-derived resistance to GS-1101/ Idelalisib in follicular lymphoma. Analysis of therapeutic potential combination with other kinases inhibitors
Principal investigator: Patricia Pérez Galán.Funder: Gilead .Duration: 01/07/2014Major founders
The research of this group can be carried out thanks to the funders.
More about researchCheck job offersIDIBAPS looks for talented professionals to meet the needs that appear periodically.
Enter